scPharmaceuticals (SCPH) Stock Overview
A pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SCPH Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
scPharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.94 |
| 52 Week High | US$5.65 |
| 52 Week Low | US$1.94 |
| Beta | 0.37 |
| 1 Month Change | 28.65% |
| 3 Month Change | 92.97% |
| 1 Year Change | 11.76% |
| 3 Year Change | -6.62% |
| 5 Year Change | -32.42% |
| Change since IPO | -64.96% |
Recent News & Updates
scPharmaceuticals Inc. (NASDAQ:SCPH) Soars 26% But It's A Story Of Risk Vs Reward
Jul 19
Further Upside For scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Could Introduce Price Risks After 40% Bounce
Jun 02Shareholders Will Likely Find scPharmaceuticals Inc.'s (NASDAQ:SCPH) CEO Compensation Acceptable
May 27
FDA Approval And Medicare Redesign Will Transform CKD Treatment Access
FDA approval of FUROSCIX for CKD patients significantly expands the market, boosting revenue potential and enhancing growth opportunities.Recent updates
scPharmaceuticals Inc. (NASDAQ:SCPH) Soars 26% But It's A Story Of Risk Vs Reward
Jul 19Further Upside For scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Could Introduce Price Risks After 40% Bounce
Jun 02Shareholders Will Likely Find scPharmaceuticals Inc.'s (NASDAQ:SCPH) CEO Compensation Acceptable
May 27FDA Approval And Medicare Redesign Will Transform CKD Treatment Access
FDA approval of FUROSCIX for CKD patients significantly expands the market, boosting revenue potential and enhancing growth opportunities.Market Cool On scPharmaceuticals Inc.'s (NASDAQ:SCPH) Revenues Pushing Shares 30% Lower
Apr 04scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
Nov 19Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term
Nov 18Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?
Jun 27scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable
Jun 27The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 16Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?
Nov 25scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients
Oct 20FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure
Oct 10Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?
Jan 11Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?
Sep 02scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX
Aug 26Shareholder Returns
| SCPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 12.8% | -1.1% | 0.9% |
| 1Y | 11.8% | -10.0% | 14.8% |
Return vs Industry: SCPH exceeded the US Pharmaceuticals industry which returned -10% over the past year.
Return vs Market: SCPH underperformed the US Market which returned 14.8% over the past year.
Price Volatility
| SCPH volatility | |
|---|---|
| SCPH Average Weekly Movement | 12.0% |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SCPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SCPH's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 163 | John Tucker | www.scpharmaceuticals.com |
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company’s lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector.
scPharmaceuticals Inc. Fundamentals Summary
| SCPH fundamental statistics | |
|---|---|
| Market cap | US$260.79m |
| Earnings (TTM) | -US$90.78m |
| Revenue (TTM) | US$41.98m |
Is SCPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCPH income statement (TTM) | |
|---|---|
| Revenue | US$41.98m |
| Cost of Revenue | US$13.05m |
| Gross Profit | US$28.94m |
| Other Expenses | US$119.72m |
| Earnings | -US$90.78m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.72 |
| Gross Margin | 68.92% |
| Net Profit Margin | -216.24% |
| Debt/Equity Ratio | -995.7% |
How did SCPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/20 16:46 |
| End of Day Share Price | 2025/07/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
scPharmaceuticals Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | BMO Capital Markets Equity Research |
| null null | BMO Capital Markets Equity Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |